Clearance of persistent hepatitis C virus infection using a claudin-1-targeting monoclonal antibody

Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer. Cell entry of HCV and other pathogens is mediated by tight junction (TJ) proteins, but successful therapeutic targeting of TJ proteins has not been reported yet. Using a human liver–chimeric mouse model, we show that a monoclonal antibody specific for the TJ protein claudin-1 (ref. 7) eliminates chronic HCV infection without detectable toxicity. This antibody inhibits HCV entry, cell-cell transmission and virus-induced signaling events. Antibody treatment reduces the number of HCV-infected hepatocytes in vivo, highlighting the need for de novo infection by means of host entry factors to maintain chronic infection. In summary, we demonstrate that an antibody targeting a virus receptor can cure chronic viral infection and uncover TJ proteins as targets for antiviral therapy.

[1]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[2]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[3]  J. Bergelson,et al.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[5]  K. Koike,et al.  Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.

[6]  Sam Griffiths-Jones,et al.  The microRNA Registry , 2004, Nucleic Acids Res..

[7]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[9]  A. Shavinskaya,et al.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Bartenschlager,et al.  Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses , 2006, Journal of Virology.

[11]  Alejandro A. Schäffer,et al.  A Fast and Symmetric DUST Implementation to Mask Low-Complexity DNA Sequences , 2006, J. Comput. Biol..

[12]  Eva Herrmann,et al.  The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells , 2006, Journal of Virology.

[13]  S. Pfeffer.  Identification of virally encoded microRNAs. , 2007, Methods in enzymology.

[14]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[15]  R. Bartenschlager,et al.  Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant , 2007, Journal of Virology.

[16]  Janice M Reichert,et al.  Handbook of therapeutic antibodies , 2007 .

[17]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[18]  J. Galmiche,et al.  Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators , 2008, Gut.

[19]  G. Reynolds,et al.  Hepatitis C virus receptor expression in normal and diseased liver tissue , 2007, Hepatology.

[20]  G. Reynolds,et al.  University of Birmingham CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry , 2008 .

[21]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[22]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[23]  Mariagrazia Pizza,et al.  CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human Hepatocytes , 2008, Journal of Virology.

[24]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[25]  R. Bartenschlager,et al.  Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations , 2009, PLoS pathogens.

[26]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[27]  François-Loïc Cosset,et al.  Inhibition of hepatitis C virus infection by anti‐claudin‐1 antibodies is mediated by neutralization of E2–CD81–Claudin‐1 associations , 2010, Hepatology.

[28]  J. McKeating,et al.  Claudin Association with CD81 Defines Hepatitis C Virus Entry , 2010, The Journal of Biological Chemistry.

[29]  J. McKeating,et al.  Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. , 2010, Gastroenterology.

[30]  Arvind H. Patel,et al.  Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation , 2010, The Journal of experimental medicine.

[31]  R. Purcell,et al.  Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. , 2010, The Journal of infectious diseases.

[32]  Thomas Lengauer,et al.  Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. , 2011, Cell host & microbe.

[33]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[34]  S. Luo,et al.  RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. , 2011, RNA.

[35]  Ana Kozomara,et al.  Reducing ligation bias of small RNAs in libraries for next generation sequencing , 2012, Silence.

[36]  Christopher T. Jones,et al.  A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo , 2012, Hepatology.

[37]  S. Pfeffer,et al.  Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells , 2012, Journal of Virology.

[38]  L. Komuves,et al.  Hepatitis C Virus Induces Epidermal Growth Factor Receptor Activation via CD81 Binding for Viral Internalization and Entry , 2012, Journal of Virology.

[39]  C. Sasakawa,et al.  Shigella targets epithelial tricellular junctions and uses a noncanonical clathrin-dependent endocytic pathway to spread between cells. , 2012, Cell host & microbe.

[40]  M. Hiet,et al.  Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. , 2012, Gastroenterology.

[41]  L. Terracciano,et al.  Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. , 2012, Gastroenterology.

[42]  L. Kaderali,et al.  MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles , 2012, PLoS pathogens.

[43]  Johan Neyts,et al.  The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.

[44]  G. Reynolds,et al.  Functional Analysis of Claudin-6 and Claudin-9 as Entry Factors for Hepatitis C Virus Infection of Human Hepatocytes by Using Monoclonal Antibodies , 2013, Journal of Virology.

[45]  P. Aubert,et al.  Effects of oral administration of rotenone on gastrointestinal functions in mice , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[46]  J. McKeating,et al.  Heterogeneous Claudin-1 Expression in Human Liver , 2013, Hepatology.

[47]  François-Loïc Cosset,et al.  HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. , 2013, Cell host & microbe.

[48]  G. Yoon,et al.  Claudin-1 induces epithelial–mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells , 2013, Oncogene.

[49]  Qianjun Li,et al.  The interaction between claudin-1 and dengue viral prM/M protein for its entry. , 2013, Virology.

[50]  M. Imamura,et al.  Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice , 2013, Gut.

[51]  David L. Thomas,et al.  Global control of hepatitis C: where challenge meets opportunity , 2013, Nature Medicine.

[52]  F. Cosset,et al.  Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner , 2014, Hepatology.

[53]  S. Dübel,et al.  Handbook of Therapeutic Antibodies: Dübel/Handbook of Therapeutic Antibodies , 2014 .

[54]  F. Chisari,et al.  Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver , 2014, Hepatology.

[55]  J. Marescaux,et al.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  L. Kaderali,et al.  Isolate‐dependent use of claudins for cell entry by hepatitis C virus , 2014, Hepatology.

[57]  A. Barnes.  The tetraspanin CD81 dynamics: investigating the role in hepatitis C virus entry , 2015 .

[58]  Barnett,et al.  Supplementary References , 2022 .